What is JBIO's market cap?

$956.50M, based on the Nov 4 close of $15.04.

Does Jade Biosciences pay a dividend?

No regular cash dividend has been paid in the last year.

How much of JBIO is sold short?

11.2M shares, 20.7% of float, as of Oct 15, 2026.

What sector is JBIO in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · JBIOHealthcarePharmaceuticals

Jade Biosciences, Inc. Common Stock (JBIO)

$15.04+3.23%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$15.04▲ 67.11% in range

Nov 4, 2025Low $8.95 · High $26.85Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Jade Biosciences closed at $15.04 on Nov 4, up 3.23%, 44.0% below its 52-week closing high. Volume of 1.1M shares was 1.22× its 20-day average (close to normal).

Split-adjusted performance: +12.2% over one month, -40.2% over six months, +58.8% over one year.

Short interest was 11.2M shares at the Oct 15 settlement, down 7.5% from the prior report (20.7% of float, 10.9 days to cover).

Market cap$956.5M63.6M shares

Revenue · quarter$0.00—

Diluted EPS$-0.76—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range8.95 – 26.85−44.0% from high

Volume1.1M1.22× 20-day avg

Volatility · 60d52.6%Annualised

Short % of float20.7%10.9 days to cover

Net cash$461.2MCash $461.2M

Next earnings—Not scheduled

Split-adjusted performance

1W +3.1%1M +12.2%3M −32.4%6M −40.2%YTD −2.5%1Y +58.8%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum33

Revenue growth—

Net margin—

Value (low P/E)—

Size70

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short11.2M−7.5% vs prior

Days to cover10.9Settled Oct 15

% of float20.7%

Short vol. 10d58.6%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
JBIOJade Biosciences	$15.04	+3.23%	−40.2%	—	—	—	$956.5M
SVRASavara	$4.66	−1.89%	−11.6%	—	—	—	$957.4M	Compare
RIGLRigel Pharmaceuticals Inc. (New)	$51.29	+4.97%	+92.3%	−22.6%	22.0%	3.0	$958.1M	Compare
ORICOric Pharmaceuticals	$9.34	−2.61%	+0.4%	—	—	—	$968.1M	Compare
SNDXSyndax Pharmaceuticals	$10.45	−26.87%	−49.4%	+81.6%	−59.3%	—	$933.2M	Compare
LTGOLatigo Biotherapeutics	$14.04	−3.64%	—	—	—	—	$930.8M	Compare
MLTXMoonLake Immunotherapeutics	$11.56	−1.20%	−34.7%	—	—	—	$983.8M	Compare
ANROAlto Neuroscience	$23.30	+2.64%	−4.9%	—	—	—	$914.3M	Compare
CRVSCorvus Pharmaceuticals	$10.57	+7.53%	−31.6%	—	—	—	$889.2M	Compare

News about Jade Biosciences

All news →

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of DirectorsGlobeNewswire Inc. · Jun 26, 2026▲ Positive Jade Biosciences Announces Pricing of Public Offering of Common StockGlobeNewswire Inc. · Jun 4, 2026▲ Positive Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA NephropathyGlobeNewswire Inc. · Jun 1, 2026▲ Positive Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Apr 23, 2026▲ Positive Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire Inc. · Mar 6, 2026▲ Positive

Quick answers

What does Jade Biosciences do?: Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy.
What is JBIO's market cap?: $956.50M, based on the Nov 4 close of $15.04.
Does Jade Biosciences pay a dividend?: No regular cash dividend has been paid in the last year.
How much of JBIO is sold short?: 11.2M shares, 20.7% of float, as of Oct 15, 2026.
What sector is JBIO in?: Healthcare, in the Pharmaceuticals industry.

About Jade Biosciences

Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

HQ: Waltham, MA55 employeesListed Apr 29, 2025jadebiosciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology